{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:14:55Z","timestamp":1789370095493,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Cancer Center Research and Development Fund","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"The Japan Agency for Medical Research and Development","award":["Practical Research for Innovative Cancer Control"],"award-info":[{"award-number":["Practical Research for Innovative Cancer Control"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00277-016-2800-1","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T02:17:42Z","timestamp":1474856262000},"page":"2017-2022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era"],"prefix":"10.1007","volume":"95","author":[{"given":"Sayako","family":"Yuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"2800_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/nejm198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg S (1984) The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med 311:1471\u20131475. doi: 10.1056\/nejm198412063112303","journal-title":"N Engl J Med"},{"issue":"2 Suppl 2","key":"2800_CR2","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Oncol 25(2 Suppl 2):11\u201316","journal-title":"Semin Oncol"},{"issue":"5 Suppl 5","key":"2800_CR3","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol 20(5 Suppl 5):75\u201388","journal-title":"Semin Oncol"},{"key":"2800_CR4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Celigny P (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 15:1110\u20131117","journal-title":"J Clin Oncol"},{"key":"2800_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Hudson GV, Linch DC (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516\u2013522. doi: 10.1016\/s0140-6736(03)14110-4","journal-title":"Lancet"},{"key":"2800_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ (2004) Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22:1454\u20131459. doi: 10.1200\/JCO.2004.10.086","journal-title":"J Clin Oncol"},{"key":"2800_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","volume":"28","author":"E Bachy","year":"2010","unstructured":"Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal-Celigny P, Salles G (2010) Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2014a study from the groupe d\u2019etude des lymphomes de l\u2019adulte. J Clin Oncol 28:822\u2013829. doi: 10.1200\/JCO.2009.22.7819","journal-title":"J Clin Oncol"},{"key":"2800_CR8","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-Celigny","year":"2012","unstructured":"Solal-Celigny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M (2012) Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 30:3848\u20133853. doi: 10.1200\/JCO.2010.33.4474","journal-title":"J Clin Oncol"},{"key":"2800_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/bjh.13895","volume":"172","author":"LJ Nastoupil","year":"2016","unstructured":"Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR (2016) Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol 172:724\u2013734. doi: 10.1111\/bjh.13895","journal-title":"Br J Haematol"},{"key":"2800_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/s1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CFE, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15:424\u2013435. doi: 10.1016\/s1470-2045(14)70027-0","journal-title":"Lancet Oncol"},{"key":"2800_CR11","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol 31:3272\u20133278. doi: 10.1200\/JCO.2012.48.3990","journal-title":"J Clin Oncol"},{"key":"2800_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/asheducation-2009.1.523","volume":"2009","author":"ES Jaffe","year":"2009","unstructured":"Jaffe ES (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523\u2013531. doi: 10.1182\/asheducation-2009.1.523","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2800_CR13","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2008","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2008) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555\u20134562. doi: 10.1200\/JCO.2008.21.3991","journal-title":"J Clin Oncol"},{"key":"2800_CR14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"2800_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. doi: 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2800_CR16","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-Celigny","year":"1998","unstructured":"Solal-Celigny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C, Gabarre J, Pignon B, Tertian G, Bouabdallah R, Rossi JF, Doyen C, Coiffier B (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16:2332\u20132338","journal-title":"J Clin Oncol"},{"key":"2800_CR17","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732. doi: 10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"key":"2800_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M (2013) ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 24:561\u2013576. doi: 10.1093\/annonc\/mds517","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2800-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:40:44Z","timestamp":1498347644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2800-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2800-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}